Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland

Early benefit assessment in Germany under the legislative framework of AMNOG (Arzneimittelmarktneuordnungsgesetz) requires direct comparisons of the new drug with appropriate comparators determined by the Federal Joint Committee (G-BA). In case no head-to-head studies are available for direct compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebioda, Andrea, Gasche, David, Dippel, Franz-Werner, Theobald, Karlheinz, Plantör, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502065/
https://www.ncbi.nlm.nih.gov/pubmed/26208931
http://dx.doi.org/10.1186/s13561-014-0031-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502065/
https://www.ncbi.nlm.nih.gov/pubmed/26208931
http://dx.doi.org/10.1186/s13561-014-0031-5

Ejemplares similares